PUMA BIOTECHNOLOGY INC news, videos and press releases
For more news please use our advanced search feature.
PUMA BIOTECHNOLOGY INC - More news...
PUMA BIOTECHNOLOGY INC - More news...
- Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
- Puma Biotechnology to Present Clinical Data on Neratinib at the AACR Annual Meeting 2025
- Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
- Puma Biotechnology to Present at Barclays Annual Global Healthcare Conference
- Puma Biotechnology to Present at Barclays Annual Global Healthcare Conference
- Puma Biotechnology Reports Fourth Quarter and Full Year 2024 Financial Results
- Puma Biotechnology to Present at TD Cowen’s 45th Annual Health Care Conference
- Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2024 Financial Results
- Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
- Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
- Puma Biotechnology’s NERLYNX® Included in NCCN Clinical Practice Guidelines for the Treatment of Cervical Cancer with a HER2 Mutation
- Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
- Puma Biotechnology Announces Initiation of ALISCA™-Breast1 Phase II Trial of Alisertib in Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer
- Puma Biotechnology Announces FDA Clearance of IND for Alisertib in Small Cell Lung Cancer
- Puma Biotechnology Reports Second Quarter Financial Results
- Puma Biotechnology to Host Conference Call to Discuss Second Quarter 2023 Financial Results
- Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
- Puma Biotechnology Announces Presentation of Biomarker Findings from a Phase II Study of Alisertib with Paclitaxel versus Paclitaxel Alone in Metastatic or Locally Recurrent Breast Cancer at the 2023 ASCO Annual Meeting
- Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
- Puma Biotechnology Reports First Quarter Financial Results
- Puma Biotechnology to Host Conference Call to Discuss First Quarter 2023 Financial Results
- Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
- Puma Biotechnology Announces Publication of Phase II Clinical Trial of Alisertib in JAMA Oncology
- Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
- Puma Biotechnology Reports Fourth Quarter and Full Year Financial Results
- Puma Biotechnology to Participate in a Panel Discussion at Cowen’s 43rd Annual Health Care Conference
- Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2022 Financial Results
- Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
- Puma Biotechnology’s NERLYNX® Included in NCCN Clinical Practice Guidelines for the Treatment of Breast Cancer with a HER2 Mutation
- Puma Biotechnology to Present at B. Riley Securities’ 3rd Annual Oncology Conference
